AGT, has a broad viral vector delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its platform of innovations that accelerate the development of a wide variety of drug candidates. From this foundation, AGT pursues exciting clinical "cures" in large and orphan indications and complex diseases. AGT's proprietary platform technologies provide reusable components that allow AGT and its internationally
recognized collaborators to create new therapies in a fraction of the time of traditional drug development and other drug companies. AGT began clinical trials this year for an HIV cure. AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its viral vector platform and patented methods.
recognized collaborators to create new therapies in a fraction of the time of traditional drug development and other drug companies. AGT began clinical trials this year for an HIV cure. AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its viral vector platform and patented methods.
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
AGT103-T, HIV Cure
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
